Follow
Jing Pei
Jing Pei
Ph.D., Pharmaceutical Sciences, University of Florida
Verified email at ufl.edu - Homepage
Title
Cited by
Cited by
Year
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ...
Nature medicine 25 (12), 1938-1947, 2019
4012019
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity
D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ...
Nature communications 12 (1), 6896, 2021
732021
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
X Zhang, Y He, P Zhang, V Budamagunta, D Lv, D Thummuri, Y Yang, ...
European journal of medicinal chemistry 199, 112397, 2020
422020
Piperlongumine conjugates induce targeted protein degradation
J Pei, Y Xiao, X Liu, W Hu, A Sobh, Y Yuan, S Zhou, N Hua, ...
Cell Chemical Biology 30 (2), 203-213. e17, 2023
242023
Identification of Piperlongumine (PL) as a new E3 ligase ligand to induce targeted protein degradation
J Pei, Y Xiao, X Liu, W Hu, A Sobh, Y Yuan, S Zhou, N Hua, ...
biorxiv, 2022.01. 21.474712, 2022
102022
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun 12: 6896
D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ...
82021
Preliminary exploration of a novel type high-efficiency mosquito-repellent compound essential oils
P Jing, Z Yin, S Yizhe, W Tao, Y Jingya
Animal Husbandry and Feed Science 6 (4), 170, 2014
12014
The system can't perform the operation now. Try again later.
Articles 1–7